pennystockhaven
  • Facebook
  • Google
  • Pinterest
  • Twitter
  • Youtube
  • Rss
Day-Trading Penny Stocks
  • Home
  • Services
  • Contact Us
Home» Commentary » Cyclacel Pharmaceuticals (CYCC): Recommendation to Continue SEAMLESS Phase 3 Study by DSMB

Cyclacel Pharmaceuticals (CYCC): Recommendation to Continue SEAMLESS Phase 3 Study by DSMB

Posted on October 13, 2011 by PennyStockHaven in Commentary, Stock Market News - No Comments
penny markets CYCC logo

Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) today announced that the independent Data Safety Monitoring Board (DSMB) of SEAMLESS, recommended that the Phase 3, randomized, registration-directed study of sapacitabine in elderly patients with acute myeloid leukemia (AML) should enter the randomized stage as planned.

Judy H. Chiao , M.D., Vice President, Clinical Development and Regulatory Affairs of Cyclacel, commented:

“The DSMB’s recommendation to continue our SEAMLESS Phase 3 study of sapacitabine in patients aged 70 years or older who are not candidates for or have refused intensive induction chemotherapy confirms that the treatment regimen of administering sapacitabine in alternating cycles with decitabine is safe and tolerable in the multicenter setting. The objective of the randomized stage of the study is to establish the role of sapacitabine in the front-line treatment of AML in this population with a high unmet medical need”

Read full press release here.

CYCC stock traded 2fold of its 10day average volume as of 12:30 p.m. EST with posted gains of 25%.


penny markets CYCC logoCyclacel Pharmaceuticals, Inc.
200 Connell Drive
Suite 1500
Berkeley Heights, NJ 07922
Tel: 908-517-7330
Fax: 866-271-3466
http://www.cyclacel.com

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.Sapacitabine (CYC682), an orally-available, cell cycle modulating, nucleoside analogue, is in Phase 3 development for the front-line treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes, lung cancer and chronic lymphocytic leukemia.Seliciclib (CYC202 or R-roscovitine), an orally-available, CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine.

CYCC, Data Safety Monitoring Board, DSMB, Nasdaq penny markets

Search

Real Time Alerts:

Tweets by @PennyStockHaven

Updates

  • Dynagas LNG Partners LP (NYSE: DLNG) Coming Off Of Bottom

    February 1, 2019
  • Histogenics Corporation (HSGX) market: only upside from these levels

    September 5, 2018
  • Quantum Corp. (QTM): Appointed Jamie Lerner as Chief Executive Officer and President

    June 26, 2018
  • FuelCell Energy (NASDAQ:FCEL) A picture is worth a thousand words

    June 22, 2018
  • Light Engine Design Corp (TLED): 50% gain into your pocket

    November 7, 2017
  • This Oil Company Is Poised For A Huge Run

    October 24, 2017
  • Curis, Inc. (CRIS) – Alert is still in Effect

    October 11, 2017
  • Curis, Inc. (CRIS) – Volume Alert (Technical Play)

    October 4, 2017
  • Trading idea with Ocean Power Technologies (Nasdaq: OPTT)

    April 26, 2017
  • Trading idea with ParkerVision, Inc. (NASDAQ: PRKR)

    April 12, 2017
  • Trading Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR)

    April 3, 2017
  • Gevo, Inc. (GEVO): Hit the Bottom

    March 12, 2017
    Micro & Small Cap Stocks

    * required

    *



    *



     
    Remember, if you’re not fully satisfied with our service, you can always opt-out of receiving our newsletter. We don’t spam and we’ll never sell your email to anyone else. We respect our subscribers’ privacy.

    Site

    • Home
    • Services
    • Contact Us
    • About Us
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    • Publishers

    Stocks

    • Financial Network
    • Free Investment Newsletter
    • Penny Stocks
    • Public Relations and Subscription Services
    eBay sniper

    Financial Network

    Yahoo Finance
    Reuters
    The Motley Fool
    WSJ
    CNBC
    Business Week
    The Street
    Bloomberg

    psh sloganYour Everything Penny Stocks Resource



    Copyright © 2018 PennyStockHaven.com. All Rights Reserved